The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2021 | Tailored therapy in Waldenström’s macroglobulinemia
Jorge Castillo, MD, of the Dana-Farber Cancer Institute, Boston, MA, explains how tailored therapy is currently being used to manage Waldenström’s macroglobulinemia, commenting on the need for more studies investigating optimal sequencing. Dr Castillo explains the various factors that need to be taken into consideration whilst determining the optimum therapy, such as the toxicity profiles of the agents and potential issues with administration. In the case of chemoimmunotherapy, issues with infusions, cytopenias, and the risk of developing secondary myeloid neoplasms need to be considered. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Disclosures
Jorge Castillo receives research funds and/or honoraria from Abbvie, Beigene, Janssen, Pharmacyclics, Roche, TG Therapeutics.
